AU2024257450A1 - Regulatable controlled expression of a transgene in primates - Google Patents

Regulatable controlled expression of a transgene in primates

Info

Publication number
AU2024257450A1
AU2024257450A1 AU2024257450A AU2024257450A AU2024257450A1 AU 2024257450 A1 AU2024257450 A1 AU 2024257450A1 AU 2024257450 A AU2024257450 A AU 2024257450A AU 2024257450 A AU2024257450 A AU 2024257450A AU 2024257450 A1 AU2024257450 A1 AU 2024257450A1
Authority
AU
Australia
Prior art keywords
antibody
inducer
administered
artemisinin
transgene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024257450A
Other languages
English (en)
Inventor
Victoria Fiona TORRANCE
Graham WHYTESIDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AskBio Inc
Original Assignee
AskBio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AskBio Inc filed Critical AskBio Inc
Publication of AU2024257450A1 publication Critical patent/AU2024257450A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Eyeglasses (AREA)
AU2024257450A 2023-04-17 2024-04-17 Regulatable controlled expression of a transgene in primates Pending AU2024257450A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202363459853P 2023-04-17 2023-04-17
US202363459850P 2023-04-17 2023-04-17
US63/459,853 2023-04-17
US63/459,850 2023-04-17
PCT/US2024/024837 WO2024220449A2 (fr) 2023-04-17 2024-04-17 Expression régulable et contrôlable d'un transgène chez des primates

Publications (1)

Publication Number Publication Date
AU2024257450A1 true AU2024257450A1 (en) 2025-11-27

Family

ID=93153477

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024257450A Pending AU2024257450A1 (en) 2023-04-17 2024-04-17 Regulatable controlled expression of a transgene in primates

Country Status (7)

Country Link
EP (1) EP4698662A2 (fr)
KR (1) KR20260013512A (fr)
CN (1) CN121311595A (fr)
AU (1) AU2024257450A1 (fr)
IL (1) IL323984A (fr)
MX (1) MX2025012417A (fr)
WO (1) WO2024220449A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329728B1 (en) * 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
MX2010003371A (es) * 2007-09-28 2010-05-05 Intrexon Corp Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
EP3568474A1 (fr) * 2017-01-10 2019-11-20 Intrexon Corporation Modulation de l'expression de polypeptides par l'intermédiaire de nouveaux systèmes d'expression de commutateurs géniques
GB201900741D0 (en) * 2019-01-18 2019-03-06 Synpromics Ltd Liver-specifc inducible prometers and methods of use thereof

Also Published As

Publication number Publication date
WO2024220449A9 (fr) 2025-04-03
CN121311595A (zh) 2026-01-09
WO2024220449A2 (fr) 2024-10-24
EP4698662A2 (fr) 2026-02-25
MX2025012417A (es) 2026-01-07
WO2024220449A3 (fr) 2025-01-16
IL323984A (en) 2025-12-01
KR20260013512A (ko) 2026-01-28

Similar Documents

Publication Publication Date Title
JP7492556B2 (ja) 滲出型加齢性黄斑変性の治療のための組成物
US20240033376A1 (en) Systems and methods for nucleic acid expression in vivo
JP2021513355A (ja) 非ウイルス性dnaベクター、ならびに抗体および融合タンパク質の産生のためのその使用
KR102934704B1 (ko) 내이에 대한 치료적 항체의 aav-매개 전달
KR20230020394A (ko) Tau 결합 화합물
US20190002915A1 (en) Compositions and methods for regulatable antibody expression
CN109641064A (zh) 非整合病毒递送系统及其相关方法
KR20140019303A (ko) 루푸스의 치료 또는 예방을 위한 조성물 및 방법
JP2009534424A (ja) Glp−1化合物/グルカゴン抗体組成物
CN113769058B (zh) 一种药物组合及其应用
JP2022544053A (ja) 非枯渇性b細胞阻害剤によって免疫原性を低下させるための方法および組成物
EP4698662A2 (fr) Expression régulable et contrôlable d'un transgène chez des primates
US20240180847A1 (en) Extracellular vesicles loaded with at least two different nucleic acids
US11351140B2 (en) Resolvin mimetic antibodies and uses thereof
TW202021983A (zh) 用於嗜伊紅性氣喘之抗il-33療法
RU2800914C2 (ru) Невирусные днк-векторы и их применение для продуцирования антител и слитых белков
RU2800914C9 (ru) Невирусные днк-векторы и их применение для продуцирования антител и слитых белков
CN120417942A (zh) 用于疾病治疗的基因编辑器和抗纤维化抑制剂的核酸药物组合物
JP2026512312A (ja) 抗tl1a抗体およびその調製方法並びに使用
NZ746729B2 (en) Compositions for treatment of wet age-related macular degeneration
NZ787237A (en) Compositions For Treatment of Wet Age-Related Macular Degeneration